Search
Search Results
-
Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2− Breast Cancer
Sacituzumab govitecan (TRODELVY ® ) is a first-in-class trophoblast cell-surface antigen 2 (Trop-2)–directed antibody and topoisomerase I inhibitor...
-
The prognostic impact of BMI in patients with HR+/HER2− advanced breast cancer: a study of the SONABRE registry
PurposeThis study determines the prognostic impact of body mass index (BMI) in patients with hormone receptor-positive/human epidermal growth factor...
-
Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study
PurposeData on treatments for male breast cancer patients are limited owing to rarity and underrepresentation in clinical trials. The real-world...
-
Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
Approximately 15–20% of breast cancers (BC) demonstrate HER2 overexpression/gene amplification. Historically, before the era of HER2-directed...
-
Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2− Advanced Breast Cancer in the USA?
Background and ObjectiveThere is a considerable survival benefit of alpelisib in patients with PIK3CA -mutated, hormone receptor-positive and human...
-
Efficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2− breast cancer: an umbrella review
BackgroundThe use of Cyclin-Dependent kinase 4 and 6 (CDK4/6) inhibitors has profoundly changed the challenge of endocrine therapy (ET) resistance in...
-
Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2− advanced breast cancer: a real-world evidence cohort
PurposeEverolimus in combination with endocrine therapy (ET) was formerly approved as 2nd-line therapy in HR(+)/HER2(−) advanced breast cancer (aBC)...
-
Cost-effectiveness of the addition of CDK4/6 inhibitors to standard endocrine therapy in first-line treatment of women with advanced HR+/HER2− breast cancer in Mexico
PurposeTo estimate the cost-effectiveness of adding a CDK4/6 inhibitor to standard endocrine therapy in the first-line setting for advanced HR+/HER2−...
-
Retrospective registry of patients with locally advanced/metastatic HR+/HER2− breast cancer treated in clinical practice in Andalusia
BackgroundLimited data are available regarding the real-world effectiveness and safety of Cyclin Dependent Kinase 4/6 inhibitor (CDK4/6i)...
-
Unveiling the HER2-low phenomenon: exploring immunohistochemistry and gene expression to characterise HR-positive HER2-negative early breast cancer
PurposeHER2-low breast cancer (BC) is a novel entity with relevant therapeutic implications, especially in hormone receptor (HR) positive BC. This...
-
Prognostic factors in non-metastatic HER2 ‘low’ and HER2 ‘negative’ breast cancer: single institute experience
AimComparison of prognosis and survival in human epidermal growth factor receptor 2 (HER2)-low and HER2-negative patients with early stage or locally...
-
Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
Background and ObjectivesPalbociclib is a cyclin-dependent kinase 4/6 inhibitor that is approved in the United States for the treatment of hormone...
-
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives
Amplification and/or overexpression of ERBB2 , the gene encoding HER2, can be found in 15–20% of invasive breast cancers and is associated with an...
-
First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN
PurposeTo evaluate the efficacy and safety of first-line therapy with palbociclib in a Spanish cohort treated after palbociclib approval.
...
-
Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer
PurposeDual anti-HER2 targeted therapy and chemotherapy is the current first-line standard of care for HER2 + metastatic breast cancer (MBC), with...
-
Treatment of HR+/HER2− breast cancer in urban mainland China: results from the CancerMPact Survey 2019
PurposeTo report the treatment utilization patterns for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−)...
-
P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2− Metastatic Breast Cancer—A Podcast
Stringent enrollment criteria can limit the diversity of patient populations in clinical trials and, consequently, the generalizability of clinical...
-
Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis
BackgroundThe survival outcomes in HER2-low versus HER2-zero breast cancer (BC) after neoadjuvant chemotherapy (NACT) remain unclear. The...
-
Therapeutic landscape of advanced HER2-positive breast cancer in 2022
HER2-positive breast cancer is an aggressive subtype of breast cancer with five-year survival rates of 30% for the advanced stage. The development of...
-
Relationship between HER2-low status and efficacy of CDK4/6 inhibitors in advanced breast cancer: a real-world study
Aims and objectivesHuman epidermal growth factor receptor 2 (HER2)-low breast cancer (BC) is a new entity considered a biologically distinct subtype...
